Azithromycin for mild-to-moderate COVID-19 - Authors' reply

Azithromycin for mild-to-moderate COVID-19 - Authors' reply

Показать другие версии (1)

Библиографические подробности
Главный автор:	Hinks, TSC
Другие авторы:	ATOMIC2 Trial Authors
Формат:	Journal article
Язык:	English
Опубликовано:	Elseiver 2021

Схожие документы

Azithromycin for mild-to-moderate COVID-19: author's reply
по: Hinks, TSC, и др.
Опубликовано: (2021)

Azithromycin in viral infections
по: Oliver, ME, и др.
Опубликовано: (2020)

Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
по: Elisa Baranski Lamback, и др.
Опубликовано: (2021-03-01)

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
по: Hinks, TSC, и др.
Опубликовано: (2021)

Author’s Reply—Is it really COVID-19?
по: David Chang, MD, и др.
Опубликовано: (2020-07-01)

Authors’ Reply: Vaccination, payment, and COVID-19
по: Jelena Dotlic, и др.
Опубликовано: (2021-11-01)

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
по: Lavoie, G, и др.
Опубликовано: (2024)

A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial
по: Hinks, TSC, и др.
Опубликовано: (2021)

A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections
по: Purwati, и др.
Опубликовано: (2021-01-01)

Boosting MAIT cells as immunotherapy: Context is everything
по: Hinks, TSC
Опубликовано: (2020)

WHO COVID-19 therapeutic guidelines – authors' reply
по: White, NJ, и др.
Опубликовано: (2021)

High-dose budesonide for early COVID-19 - Authors' reply
по: Hobbs, FDR, и др.
Опубликовано: (2021)

Author's reply: COVID‐19 vaccine in liver transplant recipients
по: Atsuyoshi Mita, и др.
Опубликовано: (2024-03-01)

Workup of cerebral involvement in patients with COVID-19 – authors’ reply
по: Chi-Sheng Chen, и др.
Опубликовано: (2023-05-01)

Author reply to Letters to the Editor “COVID-19 pneumonia in Taiwan”
по: Shao-Chung Cheng, и др.
Опубликовано: (2020-05-01)

Cyclosporine A and COVID19 – The COQUIMA cohort – Author's reply
по: Pablo Guisado-Vasco, и др.
Опубликовано: (2021-01-01)

Azithromycin through the Lens of the COVID-19 Treatment
по: Georgia G. Kournoutou, и др.
Опубликовано: (2022-08-01)

The use of Azithromycin and Hydroxychloroquine in the Treatment of Covid-19
по: Ma Yue, и др.
Опубликовано: (2023-01-01)

Author Correction: An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients
по: Rajan Ravichandran, и др.
Опубликовано: (2022-06-01)

Efficacy of MP1032 in hospitalised patients with COVID-19— authors’ reply
по: Petra Sager, и др.
Опубликовано: (2024-03-01)

Timing and sequence of vaccination against COVID-19 and influenza – Author's reply
по: Elisabeth A. Dulfer, и др.
Опубликовано: (2023-07-01)

COVID-19 vaccines: effectiveness and number needed to treat – Authors' reply
по: Piero Olliaro, и др.
Опубликовано: (2021-07-01)

Author Correction: Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
по: Manaf AlQahtani, и др.
Опубликовано: (2022-09-01)

Rationale for azithromycin in COVID-19: an overview of existing evidence
по: Wim Janssens, и др.
Опубликовано: (2021-01-01)

Azithromycin for COVID-19: Pharmacological Mechanisms, Challenges, and Prospects
по: Parisa Saberi-Hasanabadi, и др.
Опубликовано: (2023-12-01)

Effects of azithromycin on ventricular repolarization in children with COVID-19
по: Suleyman Sunkak, и др.
Опубликовано: (2022-07-01)

Observational study of azithromycin in hospitalized patients with COVID-19.
по: Alejandro Rodríguez-Molinero, и др.
Опубликовано: (2020-01-01)

Is ivermectin–Azithromycin combination the next step for COVID-19?
по: Hayder Mutter Al-Kuraishy, и др.
Опубликовано: (2020-01-01)

Authors' reply
по: Herbert, K, и др.
Опубликовано: (2012)

Authors' reply
по: Khan, A, и др.
Опубликовано: (2010)

Authors' reply
по: Leucht, S, и др.
Опубликовано: (2013)

The authors reply
по: Holman, R, и др.
Опубликовано: (2009)

The authors reply
по: Rahman, N, и др.
Опубликовано: (2011)

The authors' reply
по: Hobbs, F, и др.
Опубликовано: (2011)

The authors reply
по: Burdmann, E, и др.
Опубликовано: (2017)

Authors' reply
по: White, P, и др.
Опубликовано: (2011)

The authors reply
по: Collins, R, и др.
Опубликовано: (2009)

Authors' reply.
по: Garety, P, и др.
Опубликовано: (2014)

The authors reply
по: Holman, R, и др.
Опубликовано: (2008)

The authors reply
по: Kheifets, L, и др.
Опубликовано: (2011)